VEGFR2/CD309 Antikörper (pTyr1175)

Produktnummer ABIN7138916

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch VEGFR2/CD309 in IHC, ELISA und IF. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für VEGFR2/CD309 Antikörper (pTyr1175) (ABIN7138916)

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser VEGFR2/CD309 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF)

Produktdetails anti-VEGFR2/CD309 Antikörper

Bindungsspezifität: pTyr1175

Kreuzreaktivität: Human, Maus, Ratte

Aufreinigung: Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi

Immunogen: Peptide sequence around phosphorylation site of tyrosine 1175 (K-D-Y(p)-I-V) derived from Human VEGFR2.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IHC:1:50-1:100, IF:1:100-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Supplied at 1.0 mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu VEGFR2/CD309

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Andere Bezeichnung: KDR

Hintergrund:

Background: Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions

Lamalice L, et al. (2004). Oncogene.23(2): 434-445.
Takahashi T, et al. (2001). EMBO J .20(11): 2768-2778.

Aliases: CD309 antibody, CD309 antigen antibody, EC 2.7.10.1 antibody, Fetal liver kinase 1 antibody, FLK-1 antibody, FLK1 antibody, FLK1, mouse, homolog of antibody, Kdr antibody, Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody, Kinase insert domain receptor antibody, KRD1 antibody, Ly73 antibody, Protein tyrosine kinase receptor FLK1 antibody, Protein-tyrosine kinase receptor flk-1 antibody, soluble VEGFR2 antibody, Tyrosine kinase growth factor receptor antibody, Vascular endothelial growth factor receptor 2 antibody, VEGFR 2 antibody, VEGFR antibody, VEGFR-2 antibody, VEGFR2 antibody, VGFR2_HUMAN antibody

UniProt: P35968

Pathways: RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling